The latest news on mergers and acquisitions featuring Sanofi/Vigil Neuroscience, Aurobindo/Lannett and Eli Lilly and Company/Verve Therapeutics. Highlights below. 

* Sanofi Acquires Vigil Neuroscience for $470 M 
* Aurobindo To Acquire Lannett for $250 M 
* Lilly Completes Acquisition of Verve Therapeutics 

---

Sanofi Acquires Vigil Neuroscience for $470 M 
Sanofi has completed its acquisition of Vigil Neuroscience, a clinical-stage bio/pharmaceutical company focused on therapies for neurodegenerative diseases, for $470 million. The deal was announced in May 2025. 

This acquisition in neurology, one of Sanofi’s four strategic disease areas, enhances Sanofi’s early-stage pipeline and includes VG-3927, which will be evaluated in a Phase II clinical study in Alzheimer’s disease. VG-3927 is an oral small-molecule TREM2 agonist. Activating TREM2 is expected to enhance the neuroprotective function of microglia in Alzheimer’s disease, according to information from Sanofi. The deal does not include VGL101, Vigil’s second molecule program, which is not being acquired by Sanofi.  

The acquisition builds on a prior investment in Vigil by Sanofi. In June 2024, Sanofi made a $40-million strategic investment in Vigil that included the exclusive right of first negotiation for an exclusive license, grant, or transfer of rights to research, develop, manufacture, and commercialize VG-3927. 

Under the agreement, Sanofi acquired all outstanding common shares of Vigil for $8 per share in cash at closing, representing an equity value of approximately $470 million (on a fully diluted basis). In addition, Vigil’s shareholders received a non-transferable contingent value right per Vigil share, which entitles its holder to receive a deferred cash payment of $2, conditioned upon the first commercial sale of VG-3927. 

Source: Sanofi 

---

Aurobindo To Acquire Lannett for $250 M 
Aurobindo, a Hyderabad, India-based manufacturer of generics, active pharmaceutical ingredients, and injectables, has agreed to acquire Lannett, a Trevose, Pennsylvania-based generics company, for $250 million. The acquisition includes a 425,000-square-foot cGMP manufacturing facility, in Seymour, Indiana, capable of manufacturing multiple dosage forms, including tablets, capsules, powders, and liquids. The plant has an annual capacity of approximately 3.6 billion tablets. 

Source: Aurobindo 

---

Lilly Completes Acquisition of Verve Therapeutics 
Eli Lilly and Company has completed its acquisition of Verve Therapeutics, a Boston-based bio/pharmaceutical company developing genetic medicines for cardiovascular disease, in a deal worth up to $1.3 billion ($1 billion upfront and $300 million in milestone payments). The companies announced the acquisition in June (June 2025).  

Verve is developing a pipeline of gene-editing medicines designed to address the drivers of atherosclerotic cardiovascular disease (ASCVD). Verve’s lead program (VERVE-102) is an in vivo gene-editing medicine targeting PCSK9, a gene linked to cholesterol levels and cardiovascular health. The treatment may be applicable for people who have heterozygous familial hypercholesterolemia, a subset of ASCVD that affects 1 in 250 people in the general population, as well as certain patients with premature coronary artery disease. VERVE-102 is being evaluated in a Phase Ib clinical trial study and has been granted fast-track designation by the US Food and Drug Administration. 

Source: Verve Therapeutics